The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney

Abstract

See the Video Supplementary Digital Content 1 (http://links.lww.com/CONH/A5).

Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients

“…Consistent with it, it has been recently reported that elevated OPG is associated with increased 5- and 10-year risk of rapid renal decline, renal disease hospitalization, and/or deaths in elderly women [27]. Overall, these studies, mostly carried out in diabetic patients, suggest that OPG could be a biomarker for CKD progression, as reviewed in [28, 29]. Nevertheless, it remains unclear whether a similar association is present also in hypertensive patients.…”

Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria

“…Candido (2014) reported that retention of peptides like OPG associated with renal impairment may provide part of the explanation. Additionally, inflammation, observed in patients with renal injury, drives the expression of OPG.…”

Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways

“…Thus, it is controversial whether RANKL acts on RANK to protect podocytes from apoptosis. In our opinion, RANKL may exert its anti-apoptotic effect on PAN-induced podocytes by binding the decoy receptor osteoprotegerin (OPG) (Blazquez-Medela, Lopez-Novoa, & Martinez-Salgado, 2011), which acts as a survival factor for endothelial cells (Malyankar et al, 2000), pancreatic β-cells (Schrader et al, 2007) and tubular cells (Candido, 2014;Lorz et al, 2008). Contrary to the findings of Liu et al, Stefan Kiechl et al (Kiechl et al, 2013) found that RANKL was a significant and independent risk predictor of type 2 diabetes mellitus, and when they blocked RANK, the RANKL-mediated upregulation of NF-κB activation and proinflammatory genes was completely inhibited.…”